Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

20.99 +1.28 (+6.49%)
Streaming Delayed Price Updated: 11:03 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 249,939
Open 20.41
Bid (Size) 20.94 (300)
Ask (Size) 20.99 (300)
Prev. Close 19.71
Today's Range 20.14 - 20.99
52wk Range 8.410 - 24.27
Shares Outstanding 96,008,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
From Avalo Therapeutics
Via GlobeNewswire

Performance

YTD
+23.3%
+23.3%
1 Month
+15.3%
+15.3%
3 Month
+29.0%
+29.0%
6 Month
+39.3%
+39.3%
1 Year
+131.7%
+131.7%

More News

Read More
News headline image
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Ron Philip to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results ↗
Via Benzinga
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
From Avalo Therapeutics
Via GlobeNewswire
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Purchases Optional Milestone Buyout
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug ↗
Via Stocktwits
News headline image
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
From Avalo Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Avalo Therapeutics, Inc. - Common Stock publicly traded?
Yes, Avalo Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Avalo Therapeutics, Inc. - Common Stock trade on?
Avalo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Avalo Therapeutics, Inc. - Common Stock?
The ticker symbol for Avalo Therapeutics, Inc. - Common Stock is AVTX on the Nasdaq Stock Market
What is the current price of Avalo Therapeutics, Inc. - Common Stock?
The current price of Avalo Therapeutics, Inc. - Common Stock is 20.99
When was Avalo Therapeutics, Inc. - Common Stock last traded?
The last trade of Avalo Therapeutics, Inc. - Common Stock was at 08/19/26 11:03 AM ET
What is the market capitalization of Avalo Therapeutics, Inc. - Common Stock?
The market capitalization of Avalo Therapeutics, Inc. - Common Stock is 2.02B
How many shares of Avalo Therapeutics, Inc. - Common Stock are outstanding?
Avalo Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.